Bristol Myers' Zeposia expansion plans hit by Phase 3 setback in Crohn's disease
One of Bristol Myers Squibb’s top new immunology products has failed a Phase 3 study, denting hopes of growing the franchise through a new indication.
Zeposia, an oral S1P modulator, is already approved to treat multiple sclerosis and ulcerative colitis. But when given to adults with moderate to severe active Crohn’s disease, it failed to meet the primary endpoint of clinical remission at week 12 versus placebo, Bristol Myers revealed Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
